Introduction
Hematopoiesis is a complex process in which progenitor cells differentiate to form mature blood forms in a highly regulated manner. Chromosomal translocations frequently occur in leukemia and contribute to its development by disrupting normal hematopoiesis. Translocation t(15;17)(q22;q21) is detected in the majority of patients with acute promyelocytic leukemia (APL), a disease characterized by a block in myeloid cell differentiation at the promyelocyte stage. This translocation is a diagnostic hallmark of APL that has not been observed in other subtypes of acute myeloid leukemia (Warrell et al., 1993; Melnick and Licht, 1999; Zelent et al., 2001) ; it generates a fusion protein composed of portions of a RING finger protein, PML, and the retinoic acid receptor (RAR) a. PML-RARa protein can interact with wild-type RARa and with PML resulting in a dominant phenotype.
In addition to PML-RARa, four other APL-associated RARa-containing fusion genes have been identified in APL patients to date and characterized at the molecular level -PLZF-RARa, NPM-RARa, nuclear mitotic apparatus protein-retinoic acid receptor a (NuMA-RARa), and STAT5b-RARa (Zelent et al., 2001) . NuMA-RARa fusion protein was originally described in a 6-month-old boy with APL harboring a translocation t(11;17)(q13;q21), who was disease free after all-trans retinoic acid (ATRA) therapy (Wells et al., 1997) . This fusion protein consists of 1883 amino-acid sequences from NuMA -its N-terminal globular domain and a large coiled-coil domain -fused to the DNA-binding domain and ligand binding domain from RARa -identical portions of RARa found in all other APL fusion proteins. It has recently been demonstrated that protein-protein interaction domains including the coiled-coil domain within two of the RARa fusion partners -PML (Perez et al., 1993) and Stat5b (Dong and Tweardy, 2002) -and the poxvirus and zinc finger (POZ) domain within PLZF (Dong et al., 1996) are essential for the oncogenic activity of their respective APL-fusion proteins. The molecular basis for NuMARARa-mediated block in myeloid differentiation and the response of NuMA-RARa-positive APL disease to ATRA is not known. In particular, the contribution of the dimerization or coiled-coil domain of NuMA-RARa to its oncogenic functions has not been evaluated.
In normal myeloid cells, PML is localized to nuclear bodies (NB) or PML oncogenic domains (POD). The overexpression of PML-RARa changes the pattern of PML distribution within the nucleus from POD to a microparticulate pattern (Melnick and Licht, 1999) . This change can be reversed by treatment with ATRA and correlates to a favorable response to ATRA, which, in combination with chemotherapy, confers significant improvement in survival (Warrell et al., 1993) .
NuMA is localized to the spindle apparatus where it performs several cell cycle-specific functions including organization of the mitotic apparatus during interphase. A unique feature of NuMA is its unusually large central a-helical rod of approximately 1500 amino acid flanked by proline-rich globular termini, which functionally serve as dimerization surface (Compton and Cleveland, 1993) . It is not known what the intracellular localization of NuMA-RARa is vs NuMA. Also, unexplored is the effect of ATRA and the contribution of the dimerization or coiled-coil domain on the intracellular localization of NuMA-RARa.
To determine the molecular bases for myeloid maturation arrest in NuMA-RARa-positive APL, we examined the ability of NuMA-RARa to bind retinoic acid response element (RARE), to effect RARa/RXRa functions and to interact with the nuclear receptor corepressor, SMRT, and coactivator, TRAM-1. In addition, we determined its intracellular localization. To assess the contribution of the NuMA coiled-coil domain to these processes, we compared the findings obtained with NuMA-RARa with those obtained using NuMA-RARa in which the coiled-coil domain was deleted, NuMA-RARa(DCC). We demonstrated that NuMA-RARa binds RARE as either a homodimer or as a heterodimer with RXRa, inhibits RARa transcriptional activity, augments Stat3 transcriptional activity, forms a complex with wild-type NuMA in vitro and
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NuMA-RARα aa216 aa1700 aa1883 aa2286 The dimerization domain of NuMA-RARa in APL S Dong et al colocalized with NuMA in the nucleus. Thus, NuMARARa appears to contribute to myeloid maturation arrest by binding to RAREs and interfering with RARa/RXRa transcriptional activity, augmenting the activity of the oncogene Stat3 and perhaps by transcriptional squelching. The dimerization or coiled-coil domain of NuMA-RARa plays a pivotal role in each these oncogenic functions as well as in its nuclear localization.
Results

Transactivating properties of NuMA-RARa
It is well known that PML-RARa and PLZF-RARa have a dominant-negative effect on wild-type RAR/ RXR gene transcriptional activity (Melnick and Licht, 1999) . In this study, we determined the effects of NuMA-RARa on RA transcriptional activities using as the reporter gene construct, the vector RARE3-tkluc, which contains three tandem copies of the RARE (Figure 1) . Transfection of the HepG2 cell line with this reporter construct followed by exposure to ATRA resulted in its transactivation by endogenous RARs (Figure 1b, lane 1) . Transfection of HepG2 cells with the RARE reporter and a wild-type RARa construct followed by exposure to ATRA resulted in increased ATRA-dependent transactivation, indicating that RARa can transactivate this element ( Figure 1b, lane 2) . Substitution of wild-type RARa with PLZF-RARa resulted in a dominant-negative effect on endogenous RAR activity (Figure 1b , lane 5) as previously described (Chen et al., 1994; Dong et al., 1996) . Transfection with NuMA-RARa inhibited endogenous RAR activity ( Figure 1b, lane 3) , while NuMA-RARa(DCC) augmented endogenous RAR activity similar to wild-type RARa (Figure 1b, lane 4) . These findings indicate that, similar to other APL fusion proteins, NuMA-RARa inhibits transactivation by wild-type RARa and that the ahelical coiled-coil domain of NuMA plays a critical role in this inhibitory activity.
NuMA-RARa augments the transcriptional activity of STAT3
We and others have reported previously that in addition to inhibiting the activity of RARa, the APL fusion -IL-6 +IL-6 NuMA-RARα -
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NuMA-RARa binds to RAREs as a homodimer and to RXRa as a heterodimer
To determine if NuMA-RARa inhibition of RARa is due, in part, to its ability to directly bind RAREs, in vitro translated NuMA-RARa protein was examined in gel-shift assays using a series of RARE duplex oligonucleotides ( Figure 3a ). NuMA-RARa can form a homodimer that binds to all RAREs tested, with DR2G to DR5G being bound more efficiently, a pattern of binding preference very similar to PML-RARa and PLZF-RARa (Dong and Tweardy, 2002) . Binding of NuMA-RARa could be competitively inhibited by 100-fold excess unlabelled RARE (Figure 3c ). The shifted band ( Figure 3b , lanes 1 and 5) corresponded to a homodimer of NuMA-RARa judging from its migration characteristics compared to heterodimers of NuMA-RARa/RXRa and NuMA-RARa(DCC)/RXRa as well as RARa/RXRa (Figure 3b and data not shown). When RXRa is added to the NuMA-RARa in the RARE binding assays, two clear retardation bands are observed with DR5G and DR5 T (Figure 3b , lanes 2 and 6). The slowest migrating band contains a pair of closely migrating bands. The slower migrating of this pair represents NuMA-RARa homodimer plus one or two molecules of RXRa, while the faster migrating band of the pair represents NuMA-RARa homodimer alone. The band in the middle region of the gel represents NuMA-RARa/RXRa heterodimer complex. Both the NuMA-RARa homodimer/RXRa band and the NuMA-RARa monomer/RXRa band were supershifted by addition of the antibody against RXRa (data not shown).
NuMA dimerization or coiled-coil domain of NuMARARa is responsible for NuMA-RARa homodimerization Deletion of the dimerization or coiled-coil domain of NuMA from NuMA-RAR prevented homodimeric DNA binding to RAREs, but did not effect its ability to form heterodimers with RXRa ( Figure 3b , lanes 3,4,7, and 8). This is reminiscent of the coiled-coil domain of PML which is responsible for the formation of stable PML-RARa homodimers (Perez et al., 1993) . (Lin et al., 1998; Dong and Tweardy, 2002) . In this study, we examined NuMA-RARa for possible interactions with GST-SMRT and GST-TRAM-1 in GST-pull down assays. NuMA-RARa bound to GST-SMRT in the absence of ATRA and was dissociated by 50% from GST-SMRT at 10 À7 m ATRA, the identical concentration at which NuMA-RARa was completely recruited to the coactivator TRAM-1 (Figure 4a) . To assess the contribution of the coiled-coil domain of NuMA-RARa to its interaction with SMRT, we compared the binding of NuMA-RARa to NuMA-RARa(DCC) in GST-SMRT pull down assays. At 10 À7 m ATRA, we found that 65% of NuMA-RARa(DCC) was released from NuMARARa(DCC)/SMRT complex, while only 40% of NuMA-RARa was released from NuMA-RARa/SMRT complex (Figure 4b ). At 10 À6 m ATRA, 90% of NuMARARa(DCC) is dissociated, while only 60% of NuMARARa is dissociated. These results indicate that, similar to PML-RARa and STAT5b-RARa (Lin and Evans, 2000; Dong and Tweardy, 2002) , the coiled-coil domain of NuMA-RARa contributes to the stability of NuMARARa/SMRT complexes.
RA-dependent degradation of transiently expressed NuMA-RARa
To determine if NuMA-RARa is degraded in cells upon ATRA treatment, COS cells were transiently transfected with NuMA-RARa and incubated without or with ATRA (10 À6 m) for 24 h. Immunoblotting revealed that the amount of NuMA-RARa was decreased by 50% in ATRA-exposed cells compared to cells incubated in medium alone, indicating that ATRA treatment induced degradation of NuMA-RARa fusion protein in transiently transfected COS cells (Figure 5a ). Similar to several of the other features of NuMA-RARa, the coiled-coil domain of NuMA-RARa is involved in its ATRA-dependent degradation since the level of NuMARARa(DCC) protein was not affected by the presence of ATRA (Figure 5b ).
NuMA-RARa can interact directly with wild-type NuMA in vivo
As part of its normal functions within cells, NuMA homodimerizes via its coiled-coil domain (Compton and Cleveland, 1993) . To determine whether or not NuMARARa can form a complex with wild-type NuMA, we performed immunoprecipitation assays using M2 tagged NuMA (Figure 5c ). M2-NuMA was able to pull down NuMA-RARa, but not PLZF-RARa or NuMA-RAR-
The dimerization domain of NuMA-RARa in APL S Dong et al a(DCC), demonstrating that NuMA can form a complex with NuMA-RARa in vivo and that the coiledcoil domain of NuMA-RARa is required to mediate this interaction.
NuMA-RARa localization in transiently transfected cells
We next wanted to determine the distribution of NuMA-RARa in cells, the contribution of the coiledcoil domain to its distribution and to compare its distribution to that of each component of the fusion gene product. To accomplish this, we subcloned the coding sequences of NuMA-RARa, NuMA-RAR- Figure 7a ). CFPRARa is localized predominantly in the nucleus in a granular pattern without or with ATRA. CFP-NuMA is localized to the nucleus in a speckled pattern without or with ATRA. In the absence of ATRA, CFP-NuMARARa was located predominantly in the cytoplasm (Figure 7a, b) , confirming data recently published by Hummel et al. (2002) in COS cells stably transfected with NuMA-RARa. In the presence of ATRA, CFPNuMA-RARa was localized predominantly within the nucleus exhibiting a speckled pattern identical to that observed with CFP-NuMA (Figure 7a, b) . Cotransfection of HeLa cells with CFP-NuMA-RARa and YFPNuMA in the absence or presence of ATRA followed by confocal fluorescent microscopy demonstrated that they colocalized within the nucleus (Figure 7c and data not shown). CFP-NuMA-RARa(DCC) was equally located within the cytoplasm and nucleus in the absence of ATRA and translocated to the nucleus in the presence of ATRA (Figure 7a ). However, in contrast to CFPNuMA-RARa, CFP-NuMA-RARa(DCC) exhibited a diffuse granular pattern within the nucleus similar to CFP-RARa. The dimerization domain of NuMA-RARa in APL S Dong et al
Discussion
In this study, we showed that NuMA-RARa binds to RAREs as a homodimer or heterodimer with RXRa. The RARE binding preferences of NuMA-RARa are very similar with that of PML-RARa and PLZF-RARa (Dong and Tweardy, 2002) . Similar to our recent findings with other APL-fusion proteins, NuMA-RARa enhanced Stat3 transcriptional activity (Dong and Tweardy, 2002) . NuMA-RARa formed a complex with SMRT that destabilized at concentrations of ATRA higher than previously demonstrated for RARa/RXRa/ SMRT, but similar to that reported for PML-RARa/ SMRT (Dong and Tweardy, 2002) . Finally, we demonstrated that NuMA-RARa can bind NuMA in vivo and localizes within the nucleus in a pattern identical to NuMA. The a-helical coiled-coil domain of NuMA in NuMA-RARa was shown to be critical for these features of NuMA-RARa including binding to RARE as a homodimer, inhibition of wild-type RARa transcriptional activity, augmentation of STAT3 transcriptional activity, stability of NuMA-RARa/SMRT complex, RA-dependent degradation of NuMA-RARa, formation of NuMA-RARa/NuMA complex, and its intranuclear localization. As previously demonstrated for other APL fusion proteins and now shown in this report for NuMA-RARa, homodimerization of APL fusion proteins is mediated through a coiled-coil domain contributed by the RARa fusion partner. There are reports that wild-type RARa interacts strongly with the ID1 domain of SMRT, while RXRa binds weakly with the ID2 domain of SMRT (Lin and Evans, 2000) . Therefore, while RARa/RXRa binds only one molecule of SMRT, APL fusion proteins such as PML-RARa homodimer can associate with two corepressor molecules thereby explaining its ability to repress transcriptional activity (Lin et al., 1998; Lin and Evans, 2000) . Although we did not perform stoichiometric analysis as part of these studies, it is likely that NuMA-RARa homodimer binds two molecules of SMRT since each molecule within the homodimer contains an ID1 binding site.
There now are several additional examples of fusion partners that add a coiled-coil domain that alters the properties of the parent transcription factor, which contributes to oncogenesis. Recently, Pelicci et al has shown that oligomerization of AML1-ETO, which is produced as a result of chromosomal translocation t(8; 21) in AML, subtype M2, is required for its oncogenic activity (Minucci et al., 2000) . Oligomerization is mediated by the coiled-coil region of ETO and is essential for recruitment of N-CoR/HDAC and transcriptional repression. Another example is TEL-AML1, which is found in up to 25% of childhood B-lineage acute lymphoblastic leukemia (ALL), in which the dimerization domain of TEL is required for its transcriptional repression of the AML1-responsive IL-3 promoter (Uchida et al., 1999) .
There are many reports that the activation of JAK-STAT pathway is involved in oncogenic activity. We recently demonstrated that PML-RARa, PLZF-RARa, STAT5b-RARa (Dong and Tweardy, 2002) as well as NPM-RARa (Dong and Tweardy, unpublished data) can increase the transcriptional activity of STAT3 in HepG2 cells. In this report, we show that NuMA-RARa has the same effect suggesting that this may be a universal feature of APL. Aberrant activation of STAT3 has been demonstrated in various human blood malignancies including leukemia and lymphoma (Xia et al., 1998) . Recently, constitutive STAT3 activity has been linked to the disease-free survival in AML (Benekli et al., 2002) .
Ab-RARα
Ab-GFP NuMA is a unique protein of the nuclear matrix that associates with centrosomes after multiple phosphorylation steps and plays a critical role in the organization of the mitotic apparatus (Compton and Cleveland, 1993) . Our data demonstrate that NuMA-RARa can form a complex with NuMA and colocalizes with NuMA in the nucleus. These findings raise the possibility that, in addition to transcriptional silencing at RARE sites and augmentation of STAT3 transcriptional activity, NuMA-RARa may sequester molecules critical for RAR transcriptional function such as RXR away from RAREs resulting in transcriptional squelching. In support of this hypothesis is the finding that NuMARARa(DCC), which does not bind NuMA and localizes within the nucleus in a pattern identical to RARa, behaves similar to wild-type RARa in transcriptional assays.
Materials and methods
Plasmids and reagents
RARa, RXRa and PLZF-RARa expression vector, APREluciferase reporter vector, GST-SMRT and GST-TRAM-1 have been described previously (Dong et al., 1996; Dong and Tweardy, 2002) . (RARE)3-tk-luciferase reporter vector which containing three copies of RARE was obtained from Dr Pierre Chambon (Strasbourg, France) (Chambon, 1996) . NuMA was subcloned into the pSG5 expression vector (Stratagene) using an EcoRI fragment which contained the full-length cDNA sequence of human NuMA in the pGW1CMV vector, a gift from Dr Compton (Hanover, New Hampshire) (Compton and Cleveland, 1993) . M2-NuMA in pSG5 was generated from pSG5-NuMA by inserting the M2 FLAG epitope sequence into the N-terminus of the NuMA sequence. NuMA-RARa was constructed in the pSG5 expression vector by fusing human NuMA and RARa using fusion-PCR technology (Yon and Fried, 1989; Sambrook et al., 2000) based on the published sequence (Wells et al., 1997) . A similar PCR approach also was applied to construct pSG5-NuMA-RARa(DCC) in which the dimerization domain, the coiled-coil domain, of NuMA is deleted (Figure 1a) . NuMA-RARa, NuMA-RARa(DCC), RARa, and NuMA open reading frame sequence were subcloned into the amino-terminus of CFP or YFP in pECFP-C1 or pEYFP-C1 vectors (Clontech) to produce CFP-NuMA-RARa, CFP-NuMA-RARa(DCC), CFP-RARa, CFP-NuMA, and YFP-NuMA expression vector by standard methods (Sambrook et al., 2000) , respectively. All constructs were confirmed by DNA sequencing, in vitro transcription/ translation assay and/or immunoblotting ( Figure 6 ). ATRA In vitro translation and gel-shift DNA-binding assays
In vitro NuMA-RARa, NuMA-RARa(DCC), and RXRa proteins were translated in TNT-coupled rabbit reticulocyte lysate (Promega) system according to the manufacturer's instructions. Translation reactions also were performed in parallel in the presence of [a-35 S] methionine followed by autoradiography (Dong et al., 1996; Dong and Tweardy, 2002) . Gel-shift assays performed with in vitro translated proteins have been described elsewhere (Dong et al., 1996) . Briefly, in vitro proteins and end-labelled RAREs were incubated for 30 min at 41C and subsequently for 30 min at room temperature in the binding buffer. Protein-DNA complexes were run on 4% polyacrylamide gels equilibrated in 0.25 Â TBE and quantitated by PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA) analysis using ImageQuant software.
In vitro protein binding assay SMRT and TRAM-1 fused to GST-protein were expressed in Escherichia coli DH5a and purified by standard methodology (Sambrook et al., 2000) . A volume of 10 ml of [a-
35 S]-methionine-labelled in vitro translated proteins (NuMA-RARa or NuMA-RARa(DCC)) were incubated with 1 mg of GST-SMRT or GST-TRAM-1 proteins conjugated to glutathione sepharose (Amersham Biosciences, Piscataway, NJ, USA) in binding buffer at 41C for 2 h without or with ATRA (Sigma). Bound proteins were washed three times with binding buffer, eluted by boiling in sample buffer, resolved by 7.5% SDS-PAGE and quantitated by PhosphorImager analysis using ImageQuant software.
Immunoblotting and coimmunoprecipitation assays
At 24-48 h after transfection with GeneJuice transfection reagent (Novagen), cells were lysed in lysis buffer as previously reported (Dong and Tweardy, 2002) . Equivalent amounts of protein were electrophoresed on 5 or 7.5% SDS-polyacrylamide gels (PAGE) and transferred to PVDF membrane (Millipore). Antibodies used for immunoprecipitation and immunoblotting were rabbit polyclonal antibody against the RARa C-terminal amino acids (C-20; Santa Cruz BioTechnology, Santa Cruz, CA, USA) and rabbit polyclonal antibody against green fluorescent protein (GFP) which crossreacts with CFP (Torrey Pines Biolabs, Houston, TX, USA). Secondary antibodies used in these studies were horseradish peroxidaseconjugated goat-anti-rabbit IgG antibody (Amersham Biosciences, Piscataway, NJ, USA). Coimmunoprecipitation assays were performed 48 h after transient transfection. Cells were lysed in RIPA buffer (1% Igepal CA-630, Sigma, 0.5% sodium deoxycholate, and 0.1% SDS in PBS buffer) for 1 h at 41C. The supernatants were precleared by addition of protein A/G agarose-conjugated (Santa Cruz) and 250 ng mouse serum (Santa Cruz). Mouse anti-FLAG M2-agarose (Sigma) was added and the mixture incubated overnight at 41C followed by washing five times with RIPA buffer, loading onto 5% SDS-PAGE gels and immunoblotting with antibody against RARa.
Confocal fluorescent microscopy
HeLa cells were maintained in DMEM media (Invitrogen) 5% charcoal-stripped FBS (Invitrogen). Cells, 24 h before transfection, were plated onto poly-d-lysine-coated coverslips in 35-mm wells at a concentration of 10 5 cells per well in media containing charcoal stripped serum. Transient expression of plasmids, CFP-NuMA-RARa, CFP-NuMA-RARa(DCC), CFP-RARa, CFP-NuMA, and YFP-NuMA was accomplished using GeneJuice transfection reagent (Novagen) as described (Dong and Tweardy, 2002) . Cells were fed with fresh media the day after transfection and allowed to recover approximately 24 h prior to addition of vehicle (ethanol) or ATRA at a final concentration 10 À6 m for 2 h as indicated (Figure 7 ). Cells were fixed as described (Stenoien et al., 1999) and imaged on LSM 510 confocal microscope (Carl Zeiss, Inc.). Representative images from single focal planes were digitally processed in an identical manner for presentation using Adobe Photoshop.
